December 2019 Vol 10, No 12
Navigators are champions for patients. Our work has the potential to keep patients engaged, educated, empowered, as well as safe from infections during chemotherapy.
The CDC marks the 10-year anniversary of its highly successful program: Preventing Infections in Cancer Patients.
Filling an Educational Void: AONN+ Announces Cancer Advocacy & Patient Education (CAPE) Lung Cancer Initiative
Cheryl Bellomo, MSN, RN, HON-ONN-CG, OCN, Amy Jo Pixley, MSN, RN, OCN, ONN-CG(T), Danelle Johnston, MSN, RN, HON-ONN, OCN
The CAPE program provides pertinent patient education, best practice information, and resources to patients at their most relevant time in their journey.
The updated National Comprehensive Cancer Network (NCCN) guideline for non–small-cell lung cancer (NSCLC; version 3.2019) is focused on improving patient outcomes with immunotherapy.
Approximately 25% of children, adolescents, and young adults with advanced cancer were eligible for a targeted therapy after genotyping of their tumors in the Pediatric Molecular Analysis for Therapy Choice (MATCH) clinical trial.
Reprogramming patients’ immune cells to treat their cancer has become the front line of cancer therapy, with chimeric antigen receptor (CAR) T-cell therapy now approved by the FDA for several blood cancers.
Enfortumab Vedotin Promising Third-Line Option for Metastatic Urothelial Cancer After Checkpoint Inhibitor
Patients with metastatic urothelial cancer receive first-line treatment with platinum-based chemotherapy and second-line treatment with a checkpoint inhibitor.
Wondering how to identify the gaps in your Navigation Program? Read this to find out.
No need to reinvent the wheel, a community needs assessment will assist in filling gaps and reducing barriers to care.
Results 1 - 12 of 12